In another phase II study, the safety and efficacy of ex vivo expanded autologous T cells primed in vivo using a MAGE-A3 multi-peptide vaccine combined with Poly-ICLC and GM-CSF were evaluated in twenty-seven myeloma patients. Here, CSF2 is linked to plasma cell myeloma.